Johnson & Johnson Revenue
Johnson & Johnson (JNJ) reported Revenue of $25.31 billion for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-23
- Johnson & Johnson revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-28 was $25.31B, a 6.60% increase year-over-year.
- Johnson & Johnson revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-29 was $24.06B, a 9.91% increase year-over-year.
- Johnson & Johnson revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-28 was $24.56B, a 9.08% increase year-over-year.
- Johnson & Johnson revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-28 was $23.99B, a 6.77% increase year-over-year.
- Johnson & Johnson revenue from contract with customer, excluding assessed tax for fiscal 2025 was $94.19B, a 6.05% increase from fiscal 2024.
- Johnson & Johnson revenue from contract with customer, excluding assessed tax for fiscal 2024 was $88.82B, a 4.30% increase from fiscal 2023.
- Johnson & Johnson revenue from contract with customer, excluding assessed tax for fiscal 2023 was $85.16B, a 6.46% increase from fiscal 2023.
- Johnson & Johnson revenue from contract with customer, excluding assessed tax for fiscal 2023 was $79.99B, a 1.59% increase from fiscal 2022.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | $25.31B 10-Q · filed 2026-07-23 | $49.37B 10-Q · filed 2026-07-23 | $73.94B derived: sum of 3 quarters · filed 2026-07-23 | $97.93B derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2026-03-29 | $24.06B 10-Q · filed 2026-04-22 | $48.63B derived: sum of 2 quarters · filed 2026-04-22 | $72.62B derived: sum of 3 quarters · filed 2026-04-22 | $96.36B derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2025-12-28 | $24.56B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $48.56B derived: sum of 2 quarters · filed 2026-02-11 | $72.30B derived: sum of 3 quarters · filed 2026-07-23 | $94.19B 10-K · filed 2026-02-11 | ||||
| 2025-09-28 | $23.99B 10-Q · filed 2025-10-22 | $47.74B derived: sum of 2 quarters · filed 2026-07-23 | $69.63B 10-Q · filed 2025-10-22 | $92.15B derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2025-06-29 | $23.74B 10-Q · filed 2026-07-23 | $45.64B 10-Q · filed 2026-07-23 | $68.16B derived: sum of 3 quarters · filed 2026-07-23 | $90.63B derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2025-03-30 | $21.89B 10-Q · filed 2026-04-22 | $44.41B derived: sum of 2 quarters · filed 2026-04-22 | $66.88B derived: sum of 3 quarters · filed 2026-04-22 | $89.33B derived: sum of 4 quarters · filed 2026-04-22 | ||||
| 2024-12-29 | $22.52B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $44.99B derived: sum of 2 quarters · filed 2026-02-11 | $67.44B derived: sum of 3 quarters · filed 2026-02-11 | $88.82B 10-K · filed 2026-02-11 | ||||
| 2024-09-29 | $22.47B 10-Q · filed 2025-10-22 | $44.92B derived: sum of 2 quarters · filed 2025-10-22 | $66.30B 10-Q · filed 2025-10-22 | $87.70B derived: sum of 4 quarters · filed 2025-10-22 | ||||
| 2024-06-30 | $22.45B 10-Q · filed 2025-07-24 | $43.83B 10-Q · filed 2025-07-24 | $65.22B derived: sum of 3 quarters · filed 2025-07-24 | $86.58B derived: sum of 4 quarters · filed 2025-07-24 | ||||
| 2024-03-31 | $21.38B 10-Q · filed 2025-04-23 | $42.78B derived: sum of 2 quarters · filed 2025-04-23 | $64.13B derived: sum of 3 quarters · filed 2025-04-23 | $85.65B derived: sum of 4 quarters · filed 2025-04-23 | ||||
| 2023-12-31 | $21.39B 10-K · filed 2024-02-16 | $42.75B derived: sum of 2 quarters · filed 2024-10-23 | $64.27B derived: sum of 3 quarters · filed 2024-10-23 | $85.16B 10-K · filed 2026-02-11 | ||||
| 2023-10-01 | $21.35B 10-Q · filed 2024-10-23 | $42.87B derived: sum of 2 quarters · filed 2024-10-23 | $63.76B 10-Q · filed 2024-10-23 | $83.70B derived: sum of 4 quarters · filed 2024-10-23 | ||||
| 2023-07-02 | $21.52B 10-Q · filed 2024-07-25 | $25.53B 10-Q · filed 2023-07-31 | $42.41B 10-Q · filed 2024-07-25 | $50.28B 10-Q · filed 2023-07-31 | $62.35B derived: sum of 3 quarters · filed 2024-07-25 | $82.35B derived: sum of 4 quarters · filed 2024-07-25 | ||
| 2023-04-02 | $20.89B 10-Q · filed 2024-05-01 | $24.75B 10-Q · filed 2023-04-28 | $40.83B derived: sum of 2 quarters · filed 2024-05-01 | $60.83B derived: sum of 3 quarters · filed 2024-05-01 | $81.04B derived: sum of 4 quarters · filed 2024-05-01 | |||
| 2023-01-01 | $19.94B 10-K · filed 2024-02-16 | $39.94B derived: sum of 2 quarters · filed 2024-02-16 | $60.15B derived: sum of 3 quarters · filed 2024-02-16 | $79.99B 10-K · filed 2025-02-13 | $94.94B 10-K · filed 2023-02-16 | |||
| 2022-10-02 | $20.00B 10-K · filed 2024-02-16 | $23.79B 10-Q · filed 2022-10-27 | $40.21B derived: sum of 2 quarters · filed 2024-02-16 | $60.05B 10-Q · filed 2023-10-27 | $71.24B 10-Q · filed 2022-10-27 | $69.82B derived: sum of 4 quarters · filed 2024-02-16 | ||
| 2022-07-03 | $20.21B 10-K · filed 2024-02-16 | $24.02B 10-Q · filed 2022-07-29 | $47.45B 10-Q · filed 2023-07-31 | $49.82B derived: sum of 3 quarters · filed 2024-02-16 | $73.16B derived: sum of 4 quarters · filed 2024-02-16 | |||
| 2022-04-03 | $19.84B 10-K · filed 2024-02-16 | $23.43B 10-Q · filed 2022-04-29 | $29.61B derived: sum of 2 quarters · filed 2024-02-16 | $52.95B derived: sum of 3 quarters · filed 2024-02-16 | $76.26B derived: sum of 4 quarters · filed 2024-02-16 | |||
| 2022-01-02 | $9.77B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $33.11B derived: sum of 2 quarters · filed 2024-02-16 | $56.42B derived: sum of 3 quarters · filed 2024-02-16 | $78.74B 10-K · filed 2024-02-16 | $93.78B 10-K · filed 2022-02-17 | |||
| 2021-10-03 | $23.34B 10-Q · filed 2022-10-27 | $46.65B derived: sum of 2 quarters · filed 2022-10-27 | $68.97B 10-Q · filed 2022-10-27 | $91.45B derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-07-04 | $23.31B 10-Q · filed 2022-07-29 | $45.63B 10-Q · filed 2022-07-29 | $68.11B derived: sum of 3 quarters · filed 2023-02-16 | $89.19B derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-04-04 | $22.32B 10-Q · filed 2022-04-29 | $44.80B derived: sum of 2 quarters · filed 2023-02-16 | $65.88B derived: sum of 3 quarters · filed 2023-02-16 | $84.21B derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-01-03 | $22.48B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $43.56B derived: sum of 2 quarters · filed 2023-02-16 | $61.89B derived: sum of 3 quarters · filed 2023-02-16 | $82.58B 10-K · filed 2023-02-16 | ||||
| 2020-09-27 | $21.08B 10-Q · filed 2021-10-29 | $39.42B derived: sum of 2 quarters · filed 2021-10-29 | $60.11B 10-Q · filed 2021-10-29 | $80.86B derived: sum of 4 quarters · filed 2021-10-29 | ||||
| 2020-06-28 | $18.34B 10-Q · filed 2021-07-29 | $39.03B 10-Q · filed 2021-07-29 | $59.77B derived: sum of 3 quarters · filed 2021-07-29 | $80.50B derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2020-03-29 | $20.69B 10-Q · filed 2021-04-30 | $41.44B derived: sum of 2 quarters · filed 2021-04-30 | $62.17B derived: sum of 3 quarters · filed 2021-04-30 | $82.73B derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-29 | $20.75B 10-K · filed 2020-02-18 | $41.48B derived: sum of 2 quarters · filed 2020-10-23 | $62.04B derived: sum of 3 quarters · filed 2020-10-23 | $82.06B 10-K · filed 2022-02-17 | ||||
| 2019-09-29 | $20.73B 10-Q · filed 2020-10-23 | $41.29B derived: sum of 2 quarters · filed 2020-10-23 | $61.31B 10-Q · filed 2020-10-23 | $81.71B derived: sum of 4 quarters · filed 2020-10-23 | ||||
| 2019-06-30 | $20.56B 10-Q · filed 2020-07-24 | $40.58B 10-Q · filed 2020-07-24 | $60.98B derived: sum of 3 quarters · filed 2020-07-24 | $81.33B derived: sum of 4 quarters · filed 2020-07-24 | ||||
| 2019-03-31 | $20.02B 10-Q · filed 2020-04-29 | $40.41B derived: sum of 2 quarters · filed 2020-04-29 | $60.76B derived: sum of 3 quarters · filed 2020-04-29 | $81.59B derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2018-12-30 | $20.39B 10-K · filed 2020-02-18 | $40.74B derived: sum of 2 quarters · filed 2020-02-18 | $61.57B derived: sum of 3 quarters · filed 2020-02-18 | $81.58B 10-K · filed 2021-02-22 | ||||
| 2018-09-30 | $20.35B 10-K · filed 2020-02-18 | $41.18B derived: sum of 2 quarters · filed 2020-02-18 | $61.19B 10-Q · filed 2019-10-28 | $81.38B derived: sum of 4 quarters · filed 2020-02-18 | ||||
| 2018-07-01 | $20.83B 10-K · filed 2020-02-18 | $40.84B 10-Q · filed 2019-07-29 | $61.03B derived: sum of 3 quarters · filed 2020-02-18 | $80.68B derived: sum of 4 quarters · filed 2020-02-18 | ||||
| 2018-04-01 | $20.01B 10-K · filed 2020-02-18 | $40.20B derived: sum of 2 quarters · filed 2020-02-18 | $59.85B derived: sum of 3 quarters · filed 2020-02-18 | $78.69B derived: sum of 4 quarters · filed 2020-02-18 | ||||
| 2017-12-31 | $20.20B 10-K · filed 2019-02-20 | $39.84B derived: sum of 2 quarters · filed 2019-02-20 | $58.68B derived: sum of 3 quarters · filed 2019-02-20 | $76.45B 10-K · filed 2020-02-18 | ||||
| 2017-10-01 | $19.65B 10-K · filed 2019-02-20 | $38.49B derived: sum of 2 quarters · filed 2019-02-20 | $56.26B 10-Q · filed 2018-10-31 | |||||
| 2017-07-02 | $18.84B 10-K · filed 2019-02-20 | $36.60B derived: sum of 2 quarters · filed 2019-02-20 | ||||||
| 2017-04-02 | $17.77B 10-K · filed 2019-02-20 | |||||||
| 2017-01-01 | $71.89B 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |